The editor in chief of Psychiatric Times, a leading psychiatric journal, has stepped forward to say the journal will disclose conflicts of interest of its editorial board to "help ensure fair and accurate reporting, as well as balanced and scientifically grounded opinion and commentary." Some board members have ties to universities and drugmakers. The Integrity in Science Watch program and The International Committee of Medical Journal Editors also weigh in on the disclosure topic.
There has been a lot of hand-wringing over inappropriate industry influence on psychiatrists, as psychiatry and pharma often work closely on clinical trials and drug education. Critics say docs need to disclose and cut down on these ties, while others say partnerships with drugmakers benefit patients, as long as researchers follow their institutions' conflict of interest rules.
- read the Pharmalot report